Cytokinetics (KK3A) Financial Statements
Cytokinetics Financial Overview
Cytokinetics's market cap is currently $7.81B. The company's EPS TTM is $-7.21; its P/E ratio is -8.74; Cytokinetics is scheduled to report earnings on November 4, 2026, and the estimated EPS forecast is $-1.29. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 88.04M | $ 18.47M | $ 7.53M | $ 94.59M | $ 70.43M |
| Gross Profit | $ 77.91M | $ -320.93M | $ -322.59M | $ -146.22M | $ -89.51M |
| Operating Income | $ -612.26M | $ -536.25M | $ -496.20M | $ -324.20M | $ -186.31M |
| EBITDA | $ -774.83M | $ -493.48M | $ -456.68M | $ -331.99M | $ -183.71M |
| Net Income | $ -784.96M | $ -589.53M | $ -526.24M | $ -388.95M | $ -215.31M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 882.22M | $ 1.08B | $ 614.82M | $ 782.58M | $ 471.64M |
| Total Assets | $ 1.42B | $ 1.40B | $ 824.32M | $ 1.01B | $ 841.32M |
| Total Debt | $ 1.28B | $ 788.68M | $ 755.77M | $ 750.30M | $ 269.93M |
| Net Debt | $ 1.16B | $ 693.82M | $ 642.75M | $ 684.72M | $ 157.26M |
| Total Liabilities | $ 2.08B | $ 1.54B | $ 1.21B | $ 1.12B | $ 597.46M |
| Stockholders' Equity | $ -659.63M | $ -135.37M | $ -386.32M | $ -107.90M | $ 243.86M |
| Cash Flow | |||||
| Free Cash Flow | $ -534.82M | $ -399.80M | $ -415.75M | $ -310.85M | $ -191.39M |
| Operating Cash Flow | $ -510.01M | $ -395.89M | $ -414.33M | $ -299.52M | $ -142.52M |
| Investing Cash Flow | $ 16.67M | $ -553.10M | $ 239.25M | $ -262.13M | $ -147.78M |
| Financing Cash Flow | $ 524.46M | $ 930.61M | $ 221.32M | $ 516.17M | $ 319.98M |
Currency in USD